Cargando…

Tocilizumab (monoclonal anti-IL-6R antibody) reverses anlotinib resistance in osteosarcoma

PURPOSE: Anlotinib, a tyrosine kinase inhibitor (TKI) has been in clinical application to inhibit malignant cell growth and lung metastasis in osteosarcoma (OS). However, a variety of drug resistance phenomena have been observed in the treatment. We aim to explore the new target to reverse anlotinib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Jiuhui, Chen, Chenglong, Sun, Kunkun, Shi, Qianyu, Wang, Boyang, Huang, Yi, Ren, Tingting, Tang, Xiaodong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315670/ https://www.ncbi.nlm.nih.gov/pubmed/37404767 http://dx.doi.org/10.3389/fonc.2023.1192472

Ejemplares similares

Anti-tumour effect of tocilizumab for osteosarcoma cell lines
por: Hagi, Tomohito, et al.
Publicado: (2020)

Current progress and open challenges for applying tyrosine kinase inhibitors in osteosarcoma
por: Chen, Chenglong, et al.
Publicado: (2022)

Integrated analysis of single-cell and bulk RNA sequencing data reveals an immunostimulatory microenvironment in tumor thrombus of osteosarcoma
por: Ji, Tao, et al.
Publicado: (2023)

The role of tumor immune microenvironment in chordoma: promising immunotherapy strategies
por: Xu, Jiuhui, et al.
Publicado: (2023)

Anlotinib Downregulates RGC32 Which Provoked by Bevacizumab
por: Liu, Zhujun, et al.
Publicado: (2022)

Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab
por: Araki, Manabu, et al.
Publicado: (2012)

Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study
por: Yuan, Min, et al.
Publicado: (2021)

Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study
por: Yuan, Min, et al.
Publicado: (2022)

Case report: Unique FLT4 variants associated with differential response to anlotinib in angiosarcoma
por: Gu, Yuanyuan, et al.
Publicado: (2022)

Efficacy of Anlotinib for the Treatment of Angiosarcoma of the Face and Neck: A Case Report
por: Ren, Biyong, et al.
Publicado: (2021)

Case Report: Anlotinib Reverses Nivolumab Resistance in Advanced Primary Pulmonary Lymphoepithelioma-Like Carcinoma With FGFR3 Gene Amplification
por: Liu, Yanyang, et al.
Publicado: (2021)

The Efficacy and Safety of Anlotinib Combined With PD-1 Antibody for Third-Line or Further-Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer
por: Zhai, Chongya, et al.
Publicado: (2021)

The Clinical Implications of Tumor Mutational Burden in Osteosarcoma
por: Xie, Lu, et al.
Publicado: (2021)

miR-135a Reduces Osteosarcoma Pulmonary Metastasis by Targeting Both BMI1 and KLF4
por: Chen, Chenglong, et al.
Publicado: (2021)

Anlotinib Reverses Multidrug Resistance (MDR) in Osteosarcoma by Inhibiting P-Glycoprotein (PGP1) Function In Vitro and In Vivo
por: Wang, Gangyang, et al.
Publicado: (2022)

Immune-Related LncRNAs Affect the Prognosis of Osteosarcoma, Which Are Related to the Tumor Immune Microenvironment
por: Huang, Qingshan, et al.
Publicado: (2021)

The Value of Anlotinib in the Treatment of Intractable Brain Edema: Two Case Reports
por: Yang, Song, et al.
Publicado: (2021)

Anlotinib: A Novel Targeted Drug for Bone and Soft Tissue Sarcoma
por: Li, Shenglong
Publicado: (2021)

Efficacy and safety of anlotinib-based treatment in metastatic breast cancer patients
por: Qian, Yu, et al.
Publicado: (2022)

Increase of Hemoglobin Levels by Anti-IL-6 Receptor Antibody (Tocilizumab) in Rheumatoid Arthritis
por: Hashimoto, Motomu, et al.
Publicado: (2014)

Efficacy and safety of anlotinib plus programmed death-1 blockade versus anlotinib monotherapy as second or further-line treatment in advanced esophageal squamous cell carcinoma: A retrospective study
por: Liu, Ying, et al.
Publicado: (2022)

Malignant mediastinal mesothelioma treated with anlotinib: a case report and review of the literature
por: Zhang, Yishi, et al.
Publicado: (2023)

circUSP34 accelerates osteosarcoma malignant progression by sponging miR‐16‐5p
por: Lou, Jingbing, et al.
Publicado: (2021)

Molecular subtypes of osteosarcoma classified by cancer stem cell related genes define immunological cell infiltration and patient survival
por: Guo, Lei, et al.
Publicado: (2022)

Chordoma recruits and polarizes tumor-associated macrophages via secreting CCL5 to promote malignant progression
por: Xu, Jiuhui, et al.
Publicado: (2023)

Integrated Transcriptome Analysis Reveals KLK5 and L1CAM Predict Response to Anlotinib in NSCLC at 3rd Line
por: Lu, Jun, et al.
Publicado: (2019)

Editorial: Tocilizumab, a Humanized Therapeutic IL-6 Receptor (IL-6R) Monoclonal Antibody, and Future Combination Therapies for Severe COVID-19
por: Parums, Dinah V.
Publicado: (2021)

Humanized Anti-hepatocyte Growth Factor Monoclonal Antibody (YYB-101) Inhibits Ovarian Cancer Progression
por: Kim, Hyun Jung, et al.
Publicado: (2019)

Evaluation of the Anti-Tumor Activity of the Humanized Monoclonal Antibody NEO-201 in Preclinical Models of Ovarian Cancer
por: Zeligs, Kristen P., et al.
Publicado: (2020)

Monoclonal antibodies in cervical malignancy-related HPV
por: Aghbash, Parisa Shiri, et al.
Publicado: (2022)

Efficacy of the anti–IL-6 receptor antibody tocilizumab in neuromyelitis optica: A pilot study
por: Araki, Manabu, et al.
Publicado: (2014)

Anlotinib Combined With Chemoradiotherapy Exhibits Significant Therapeutic Efficacy in Esophageal Squamous Cell Carcinoma
por: Shi, Jingzhen, et al.
Publicado: (2020)

Novel Nanocrystal Injection of Insoluble Drug Anlotinib and Its Antitumor Effects on Hepatocellular Carcinoma
por: Luo, Mei, et al.
Publicado: (2021)

Anlotinib for the Treatment of Multiple Recurrent Lumbar and Sacral Cord Hemangioblastomas: A Case Report
por: Jin, Nan, et al.
Publicado: (2022)

Outcomes of Anlotinib Maintenance Therapy in Patients With Advanced NSCLC in a Real-World Setting
por: Li, Jia, et al.
Publicado: (2022)

The efficacy and adverse effects of anlotinib in the treatment of high-grade glioma: A retrospective analysis
por: Shen, Fangcheng, et al.
Publicado: (2023)

Determination of the Monoclonal Antibody Tocilizumab by a Validated Micellar Electrokinetic Chromatography Method
por: Zayed, Sahar, et al.
Publicado: (2022)

Selective localisation of two radiolabelled anti-sarcoma monoclonal antibodies in human osteosarcoma xenografts.
por: Bruland, O., et al.
Publicado: (1987)

Novel infusion strategy reduces severe adverse events caused by the anti-GD2 monoclonal antibody naxitamab
por: Varo, Amalia, et al.
Publicado: (2023)

Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial
por: Ma, Jianhui, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2u3e3lp1d988go43quvrora2dn